explore -WSS

explore

author：leisure time 2025-09-06 03:55:38 - browse：85

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： New clues to why women have higher risk of autoimmune disorders

focus

WSS

Boston competes with Raleigh

Study fuels hope CAR

Investment in vaccine development is lagging, report finds

Color Health wants to make cancer screenings convenient

10 reasons why health care startups fail

Neuroscience renaissance leads to new crop of psychiatric drugs

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Alkermes shareholders re

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

George Santos makes 1st court appearance after pleading not guilty to 13 counts

10 reasons why health care startups fail

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Beam, Prozac, "TechBio" and more

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

10 reasons why health care startups fail

Heart attack and stroke risk calculators need revising

Why Medicare shouldn’t cover every FDA

hotspot

Pancreatic cancer early detection could be helped by AI

Medicare Advantage insurers face 0.2% cut to 2025 payments

Are embryos people? Reproductive medicine's future depends on the answer

Elisabeth Bik tackles the widespread issue of research misconduct

Venture capital firm's plans to take over Akron hospital face hurdles

Syphilis numbers in the United States reach record heights

focus

hotspot

hotspot

hotspot